Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cynthia Slominski

Psychiatry Los Angeles, CA Medical Doctor

NPI 1730233784 CMS profile 1039070

5201 S Vermont Ave, Los Angeles, CA 90037

Open in the dashboard

General payments

$8,831

362 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cynthia Slominski of Los Angeles, CA is reported in the CMS Open Payments database as having received $8,831 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $275 2
2024 General $680 23
2023 General $2,077 90
2022 General $2,306 106
2021 General $2,336 96
2020 General $530 21
2019 General $628 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cynthia Slominski
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Cynthia Slominski were reported at $275. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Cynthia Slominski Psychiatry median Middle half National median
2019 $628 $184 $59–$605 $163
2020 $530 $119 $36–$372 $114
2021 $2,336 $143 $43–$576 $132
2022 $2,306 $153 $50–$590 $149
2023 $2,077 $170 $56–$651 $160
2024 $680 $179 $57–$673 $164
2025 $275 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $1,876 64 payments
  2. Janssen Pharmaceuticals, Inc $1,604 62 payments
  3. Alkermes, Inc. $1,233 52 payments
  4. Teva Pharmaceuticals USA, Inc. $978 47 payments
  5. Otsuka America Pharmaceutical, Inc. $732 36 payments
  6. ITI, Inc. $695 32 payments
  7. Vanda Pharmaceuticals Inc. $428 13 payments
  8. Lundbeck LLC $332 19 payments
  9. AbbVie, Inc. $325 9 payments
  10. Indivior Inc. $229 11 payments
  11. Other $397 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,503 358 payments
  2. Education $328 4 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $1,384 57 payments
  2. INGREZZA Neuropsychiatry $1,240 39 payments
  3. INVEGA TRINZA $827 37 payments
  4. ABILIFY MAINTENA $767 44 payments
  5. VIVITROL $733 29 payments
  6. CAPLYTA $695 32 payments
  7. AUSTEDO $533 38 payments
  8. REXULTI $457 20 payments
  9. INGREZZA Neurology $419 16 payments
  10. ARISTADA $408 18 payments
  11. Other $4,427 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record